Navigation Links
Chemir Announces New Custom Synthesis Laboratory
Date:2/14/2013

St. Louis, Missouri (PRWEB) February 14, 2013

Chemir is proud to announce the opening of its new chemical synthesis laboratory. The recently renovated space expands the company’s capability to synthesize analytical standards and pharmaceutical intermediates, as well as provide process development and litigation support.

The new lab boosts the efficiency of Chemir’s team of Ph.D., M.S. and B.S. synthetic chemists, as they provide organic synthesis of compounds at the milligram to kilogram scale. The dedicated laboratory space, designed by the chemists, contains new hoods, new countertops, and updated utilities. The newly installed hoods offer greater volume and expanded utilities, expanding the range of possible reactions. The renovation is part of an extensive building improvement plan for Chemir in 2013.

The expanded organic synthesis lab also reflects a greater demand for these services to support legal challenges, including patent prosecution and infringement defense.

“We’ve worked on legal synthesis projects for a variety of cases and industries,” says Dr. Albert Lee, Senior Manager of Custom Synthesis. “For example, we supported a patent prosecution case by performing synthesis based on technology from the early 1990s. We’ve also supported infringement defense issues by synthesizing a necessary analytical standard when the opposing side was uncooperative and would not provide it.”

Chemir’s custom synthesis team was previously known as IQsynthesis and Gateway Chemical Technology. Established in 1995, the group moved to the Chemir location in 2010 and assists the pharmaceutical, agrichemical and specialty chemical industries in the early phase production of molecules for research and development. The group also provides custom synthesis services for litigation support.

About Chemir –A Division of Evans Analytical Group
Chemir provides scientific solutions with analytical services, product development and litigation support services. Since 1959 this independent laboratory has solved thousands of issues involving deformulation (reverse engineering), contaminant and impurity identification, failure analysis, analytical method development, product development, custom synthesis, patent, intellectual property, and other legal challenges for over 7000 clients. The scientific staff of 35, including 8 Ph.D. level chemists, uses state-of-the-art analytical instrumentation and expert interpretations to assist such industries as polymers, plastics, medical devices, pharmaceuticals, packaging, coatings, food and beverages, personal care products, consumer products, specialty chemicals, industrial products and more. For more information, visit http://www.chemir.com.

Read the full story at http://www.prweb.com/releases/Synthesis/Laboratory/prweb10431173.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related biology technology :

1. Keryx Biopharmaceuticals, Inc. Announces Upcoming Poster Presentations of Zerenex™ (Ferric Citrate) at the Upcoming American Society of Nephrology Kidney Week 2011 Annual Meeting
2. VaxyGen Assay Services, LLC Announces Launch of Custom Bioassay Services and Operations
3. Sequenom Announces Participation at the Lazard Capital Markets 8th Annual Healthcare Conference
4. ACORN Research, LLC Announces Partnership with AdeptBio, LLC
5. GeoVax Labs, Inc. Announces Nine Month 2011 Financial Results
6. WuXi PharmaTech Announces Third-Quarter 2011 Results
7. Chimerix Announces Late-Breaking Poster Presentation at Kidney Week 2011 Annual Meeting
8. Spherix Announces Third Quarter Financial Results
9. Modern Mobility Aids, Inc. Announces November 30, 2011 Closing of Lumigene Acquisition
10. MedImmune Announces Winners of Its 6th Annual Global Abstract Competition
11. Nile Therapeutics Announces Top-Line Results in Clinical Trial Evaluating the Subcutaneous Infusion of Cenderitide, Meets Primary Endpoint
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/8/2016)... --> ... oncology company developing next generation cancer therapeutics that ... that chairman emeritus of Tata Sons Limited, Mr ... as part of the first close of Invictus,s ... Capital and Aarin Capital. http://photos.prnewswire.com/prnh/20150923/766442 ) ...
(Date:2/8/2016)... , Feb. 8, 2016  BioElectronics Corporation ... medical devices, announced today that it is responding ... proceedings from the Securities and Exchange Commission posted ... Staelin , Chairman of the Board of BioElectronics ... of Business Administration at The Fuqua School of ...
(Date:2/8/2016)... (PRWEB) , ... February 08, 2016 , ... ... (AI) and leading supplier of Semantic Graph Database technology, today announced the availability ... release of Cloudera Enterprise through the Cloudera Certified Technology Program (CCPT). ...
(Date:2/8/2016)... 2016  Diplomat Pharmacy, Inc. (NYSE: DPLO) announced today that its new website has gone live. ... knowledge-based and mobile-friendly. Visit the new site: ... ... ... "The goal was to reimagine the website ...
Breaking Biology Technology:
(Date:1/22/2016)... 2016 http://www.researchandmarkets.com/research/p74whf/global_biometrics ... "Global Biometrics Market in Retail Sector ... --> http://www.researchandmarkets.com/research/p74whf/global_biometrics ) has announced ... Market in Retail Sector 2016-2020" report ... Research and Markets ( http://www.researchandmarkets.com/research/p74whf/global_biometrics ) has ...
(Date:1/20/2016)... , Jan. 20, 2016  Synaptics Incorporated ... human interface solutions, today announced sampling of S1423, ... for wearables and small screen applications including smartwatches, ... printers. Supporting round and rectangular shapes, as well ... excellent performance with moisture on screen, while wearing ...
(Date:1/13/2016)... DUBLIN , January 13, 2016 ... has announced the addition of the  ... - Estimation & Forecast (2015-2020)" ... http://www.researchandmarkets.com/research/7h6hnn/india_biometrics ) has announced the ... & Identification Market - Estimation & ...
Breaking Biology News(10 mins):